CN102292346B - 肥胖的治疗 - Google Patents

肥胖的治疗 Download PDF

Info

Publication number
CN102292346B
CN102292346B CN201080005151.6A CN201080005151A CN102292346B CN 102292346 B CN102292346 B CN 102292346B CN 201080005151 A CN201080005151 A CN 201080005151A CN 102292346 B CN102292346 B CN 102292346B
Authority
CN
China
Prior art keywords
peptide
seq
amino acid
calcitonin
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080005151.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102292346A (zh
Inventor
诺泽·M·梅赫塔
艾米·施蒂默尔
威廉·斯特恩
詹姆斯·P·吉利根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ugp Therapy Co ltd
KeyBioscience AG
Original Assignee
KeyBioscience AG
Unigene Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KeyBioscience AG, Unigene Laboratories Inc filed Critical KeyBioscience AG
Publication of CN102292346A publication Critical patent/CN102292346A/zh
Application granted granted Critical
Publication of CN102292346B publication Critical patent/CN102292346B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1706—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201080005151.6A 2009-01-22 2010-01-22 肥胖的治疗 Expired - Fee Related CN102292346B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20575009P 2009-01-22 2009-01-22
US61/205,750 2009-01-22
PCT/US2010/021872 WO2010085700A2 (en) 2009-01-22 2010-01-22 Treatment for obesity

Publications (2)

Publication Number Publication Date
CN102292346A CN102292346A (zh) 2011-12-21
CN102292346B true CN102292346B (zh) 2015-12-02

Family

ID=42356411

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080005151.6A Expired - Fee Related CN102292346B (zh) 2009-01-22 2010-01-22 肥胖的治疗

Country Status (11)

Country Link
US (6) US8076291B2 (OSRAM)
EP (1) EP2389388B1 (OSRAM)
JP (1) JP5753097B2 (OSRAM)
KR (1) KR20110119707A (OSRAM)
CN (1) CN102292346B (OSRAM)
AU (1) AU2010206614B2 (OSRAM)
BR (1) BRPI1006943A2 (OSRAM)
CA (1) CA2750035C (OSRAM)
DK (1) DK2389388T3 (OSRAM)
ES (1) ES2622877T3 (OSRAM)
WO (1) WO2010085700A2 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102292346B (zh) 2009-01-22 2015-12-02 关键生物科学有限公司 肥胖的治疗
JP2014502252A (ja) 2010-09-28 2014-01-30 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 作用持続時間が増した改変ポリペプチド
US9533022B2 (en) 2011-11-02 2017-01-03 KeyBioscience A/S Peptide analogs for treating diseases and disorders
MX351092B (es) * 2011-11-02 2017-10-02 Keybioscience Ag Analogos peptidicos para tratar enfermedades y trastornos.
EP3095484B1 (en) * 2011-11-02 2018-05-02 KeyBioscience AG Calcitonin mimetics for treating diseases and disorders
ES2640285T3 (es) * 2012-04-19 2017-11-02 Novo Nordisk A/S Análogos de amilina humana
CN102964452B (zh) * 2012-12-12 2015-09-09 黑龙江大学 用于治骨质疏松症和肥胖的msCT-rhLeptin融合蛋白及编码该融合蛋白的核酸
CN102965327B (zh) * 2012-12-12 2014-06-11 黑龙江大学 msCT-rhLeptin融合蛋白转基因工程菌株
WO2016034604A1 (en) 2014-09-04 2016-03-10 Novo Nordisk A/S Novel amylin and calcitonin receptor agonist
GB201500263D0 (en) * 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
EA202092442A3 (ru) 2016-06-07 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
WO2018172984A1 (en) 2017-03-23 2018-09-27 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
KR102911883B1 (ko) 2018-10-11 2026-01-13 인타르시아 세라퓨틱스 인코포레이티드 인간 아밀린 유사체 폴리펩타이드 및 사용 방법
TWI901926B (zh) 2020-12-18 2025-10-21 美商美國禮來大藥廠 雙重澱粉素及降鈣素受體促效劑及其用途
CA3266547A1 (en) 2022-08-29 2024-03-07 Eli Lilly And Company COMPOSITIONS FOR ORAL ADMINISTRATION
WO2025240893A1 (en) 2024-05-17 2025-11-20 Eli Lilly And Company 4-phenyl-1h-pyrazolo[3,4-b]pyridine-5-carboxamide derivatives as amylin and/or calcitonin receptor agonists for the treatment of type 2 diabetes, obesity or overweight

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1120549A (zh) * 1994-06-21 1996-04-17 株式会社三和化学研究所 降钙素类似物及其应用
JP2000290295A (ja) * 1999-03-31 2000-10-17 Asahi Chem Ind Co Ltd Ｎ−アセチルグルコサミニルカルシトニン
CN1424399A (zh) * 2001-12-14 2003-06-18 中国农业科学院生物技术研究所 一种新型鲑鱼降钙素类似物及其在植物油体中表达的方法
CN1980954A (zh) * 2004-02-11 2007-06-13 安米林药品公司 胰岛淀粉样多肽家族肽及其制备和使用方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US4764589A (en) 1987-05-26 1988-08-16 Rorer Pharmaceutical Corporation [N-alpha-acyl,8-glycine, des-19-leucine]-calcitonin
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
US5364840A (en) * 1989-12-05 1994-11-15 Vical, Inc. Synthetic calcitonin peptides
US5175146A (en) * 1989-12-05 1992-12-29 Vical, Inc. Synthetic calcitonin peptides
US5527771A (en) * 1991-01-10 1996-06-18 Amylin Pharmaceuticals, Inc. Methods and Compositions for treatment of diabetes mellitus, hypoglycemia & other conditions
US5580953A (en) * 1991-08-14 1996-12-03 Amylin Pharmaceuticals, Inc. Amylin antagonist peptides and uses therefor
US5527790A (en) 1991-09-30 1996-06-18 The University Of British Columbia Bis(maltolato)oxovanadium compositions for the treatment of elevated blood sugar
DE726075T1 (de) * 1995-02-08 1996-12-12 Therapicon Srl Nicht-inorganische pharmazeutische salzige Lösungen zur endonasale Verabreichung
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
CA2502764A1 (en) * 1995-08-22 1997-03-06 Japan Tobacco Inc. Amide compounds
HUP0001272A3 (en) 1997-04-16 2012-12-28 Unigene Lab Inc Direct expression of peptides into culture media
US6083480A (en) * 1997-05-01 2000-07-04 Diatide, Inc. Calcitonin receptor binding reagents
US6086018A (en) 1997-12-09 2000-07-11 Mcdonnell Douglas Corporation Interlocking assembly system for an aircraft cabin
DE602005021858D1 (de) 2004-02-11 2010-07-29 Amylin Pharmaceuticals Inc Peptide der amylin familie, verfahren zu deren herstellung und verwendung
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
GB0422644D0 (en) 2004-10-12 2004-11-10 Novartis Ag Organic compounds
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
US7671023B2 (en) * 2005-03-31 2010-03-02 Amylin Pharmaceuticals, Inc. Amylin agonist for treating depression, anxiety disorder and schizophrenia
EP1907561B1 (en) 2005-06-24 2013-08-28 Unigene Laboratories, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
CN102292346B (zh) * 2009-01-22 2015-12-02 关键生物科学有限公司 肥胖的治疗

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1120549A (zh) * 1994-06-21 1996-04-17 株式会社三和化学研究所 降钙素类似物及其应用
JP2000290295A (ja) * 1999-03-31 2000-10-17 Asahi Chem Ind Co Ltd Ｎ−アセチルグルコサミニルカルシトニン
CN1424399A (zh) * 2001-12-14 2003-06-18 中国农业科学院生物技术研究所 一种新型鲑鱼降钙素类似物及其在植物油体中表达的方法
CN1980954A (zh) * 2004-02-11 2007-06-13 安米林药品公司 胰岛淀粉样多肽家族肽及其制备和使用方法

Also Published As

Publication number Publication date
US9394342B2 (en) 2016-07-19
AU2010206614B2 (en) 2015-03-26
WO2010085700A2 (en) 2010-07-29
US20160354434A1 (en) 2016-12-08
US20120142586A1 (en) 2012-06-07
US8076291B2 (en) 2011-12-13
US8497347B2 (en) 2013-07-30
DK2389388T3 (en) 2017-05-01
US9833494B2 (en) 2017-12-05
US8217139B2 (en) 2012-07-10
US20120149635A1 (en) 2012-06-14
US8378067B2 (en) 2013-02-19
US20100311650A1 (en) 2010-12-09
CN102292346A (zh) 2011-12-21
EP2389388B1 (en) 2017-03-08
EP2389388A2 (en) 2011-11-30
EP2389388A4 (en) 2013-08-21
JP5753097B2 (ja) 2015-07-22
ES2622877T3 (es) 2017-07-07
CA2750035C (en) 2018-02-27
US20140073561A1 (en) 2014-03-13
BRPI1006943A2 (pt) 2021-06-15
US20120302497A1 (en) 2012-11-29
CA2750035A1 (en) 2010-07-29
WO2010085700A3 (en) 2010-09-23
JP2012515794A (ja) 2012-07-12
AU2010206614A1 (en) 2011-08-04
KR20110119707A (ko) 2011-11-02

Similar Documents

Publication Publication Date Title
US9833494B2 (en) Methods of treating medical conditions using peptides
US5739106A (en) Appetite regulating compositions
AU2008257448B2 (en) Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
AU2019323697B2 (en) Acylated calcitonin mimetics
AU2017348172A1 (en) Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors
AU2016247189B2 (en) Peptide analogs for treating diseases and disorders
AU2018202480A1 (en) Calcitonin mimetics for treating diseases and disorders
CN120603839A (zh) Nmu受体2激动剂
WO2018211111A1 (en) Dual amylin and calcitonin receptor agonists for treating diseases and disorders
WO2021148664A1 (en) Oxyntomodulin mimetics
MXPA97009880A (en) Apet regulatory compositions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: GUANJIAN BIOLOGICAL SCIENCE CO., LTD.

Free format text: FORMER OWNER: UGP THERAPEUTICS, INC.

Effective date: 20140710

Owner name: UGP THERAPEUTICS, INC.

Free format text: FORMER OWNER: UNIGENE LAB INC.

Effective date: 20140710

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20140710

Address after: Swiss Stans

Applicant after: KEYBIOSCIENCE AG

Address before: Illinois State

Applicant before: UGP Therapy Co.,Ltd.

Effective date of registration: 20140710

Address after: Illinois State

Applicant after: UGP Therapy Co.,Ltd.

Address before: New jersey, USA

Applicant before: Unigene Laboratories Inc.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151202

Termination date: 20200122

CF01 Termination of patent right due to non-payment of annual fee